Regenerative Medicine
Total Trials
1
As Lead Sponsor
As Collaborator
0
Total Enrollment
14
NCT05392751
Dose Escalation Study to Evaluate the Safety/Tolerability and Efficacy of EA-2353 in Subjects With Retinitis Pigmentosa
Phase: Phase 1/2
Role: Lead Sponsor
Start: Jun 2, 2022
Completion: Apr 24, 2024
Loading map...